Pharmacokinetics of mycophenolate sodium and comparison with the mofetil formulation in stable kidney transplant recipients

Clinical Journal of the American Society of Nephrology

Volumn 2, Issue 6, 2007, Pages 1147-1155

  Cattaneo, Dario ^a,b   Cortinovis, Monica ^a,b   Baldelli, Sara ^a,b   Bitto, Alessandra ^a,b   Gotti, Eliana ^a   Remuzzi, Giuseppe ^a,b   Perico, Norberto ^a,b  

^a OSPEDALI RIUNITI   (Italy)

^b Transplant Research Center   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENTERIC COATED TABLET; FEMALE; HUMAN; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; TABLETS, ENTERIC-COATED;

EID: 38449104279     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.02820707     Document Type: Article

References (23)

1. Halloran PF: Immunosuppressive drugs for kidney transplantation. N Engl J Med 351: 2715-2729, 2004
2. van Gelder T, Hilbrands LB, Vanrenterghem Y, Weimar W, de Fijter JW, Squifflet JP, Hene RJ, Verpooten GA, Navarro MT, Hale MD, Nicholls AJ: A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 68: 261-266, 1999
3. Cattaneo D, Gaspari F, Ferrari S, Stucchi N, Del Priore L, Perico N, Gotti E, Remuzzi C: Pharmacokinetics help optimizing mycophenolate mofetil dosing in kidney transplant patients. Clin Transplant 15: 402-409, 2001
4. Behrend M: Adverse gastrointestinal effects of mycophenolate mofetil: Aetiology, incidence and management. Drug Saf 24: 645-653, 2001
5. Sollinger HW: Mycophenolates in transplantation. Clin Transplant 18: 485-492, 2004
6. Budde K, Glander P, Diekmann F, Waiser J, Fritsche L, Dragun D, Heumayer HH: Review of the immunosuppressant enteric-coated mycophenolate sodium. Expert Opin Pharmacother 5: 1333-1345, 2004
7. Arns W, Breuer S, Choudhury S, Taccard G, Lee J, Binder V, Roettele J, Schmouder R: Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate sodium. Clin Transplant 19: 199-206, 2005
8. Granger DK: Enteric-coated mycophenolate sodium: Results of two pivotal global multicenter trials. Transplant Proc 33: 3241-3244, 2001
9. Johnston A, He X, Holt DW: Bioequivalence of enteric-coated mycophenolate sodium and mycophenolate mofetil: A meta-analysis of three studies in stable renal transplant recipients. Transplantation 82: 1413-1418, 2006
10. Hummel M, Yonan N, Ross H, Miller LW, Sechaud R, Balez S, Koelle EU, Gerosa G: Pharmacokinetics and variability of mycophenolic from enteric-coated mycophenolate sodium compared with mycophenolate mofetil in de novo heart transplant recipients. Clin Transplant 21: 18-23, 2007
11. Budde K, Glander P, Kramer BK, Fisher W, Hoffmann U, Bauer S, Grohmann J, Neumayer HH, Arns W: Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: Clinical, pharmacokinetic, and pharmacodynamic outcomes. Transplantation 83: 417-424, 2007
12. Budde K, Bauer S, Hambach P, Hahn U, Roblitz H, Mai I, Diekmann F, Neumayer HH, Glander P: Pharmacokinetic and pharmacodynamic comparison of enteric-coated mycophenolate sodium and mycophenolate mofetil in maintenance renal transplant recipients. Am J Transplant 7: 888-898, 2007
13. van Hest RM, van Gelder T, Bouw R, Goggin T, Gordon R, Mamelok RD, Mathot RA: Time-dependent clearance of mycophenolic acid in renal transplant recipients. Br J Clin Pharmacol 63: 741-752, 2007
14. Cattaneo D, Merlini S, Baldelli S, Bartolini B, Nicastri A, Gotti E, Remuzzi G, Perico N: Mycophenolic acid formulation affects cyclosporine pharmacokinetics in stable kidney transplant recipients. Ther Drug Monit 28: 643-649, 2006
15. Gaspari F, Perico N, Ruggenenti P, Mosconi L, Amuchastegui CS, Guerini E, Daina E, Remuzzi G: Plasma clearance of nonradioactive iohexol as a measure of glomerular filtration rate. J Am Soc Nephrol 6: 257-263, 1995
16. D'Agostino RB: Tests for normal distribution. In: Goodness-of-Fit Techniques, edited by D'Agostino RB, Stephens MA, New York, Marcel Decker, 1986
17. Fulton B, Markham A: Mycophenolate mofetil: A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation. Drugs 51: 278-298, 1996
18. Kaplan B, Meier-Kriesche HU, Minnick P, Bastien MC, Sechaud R, Yeh Cm, Balez S, Picard F, Schmouder R: Randomized calcineurin inhibitor cross over study to measure the pharmacokinetics of co-administered enteric-coated mycophenolate sodium. Clin Transplant 19: 551-558, 2005
19. Budde K, Tedesco-Silva H, Pestana JM, Glander P, Neumayer HH, Felipe CR, Machado PP, Sechard R, Schmouder R: Enteric-coated mycophenolate sodium provides higher mycophenolate acid predose levels compared with mycophenolate mofetil: Implications for therapeutic drug monitoring. Ther Drug Monit 29: 381-384, 2007
20. Shaw LM, Holt DW, Oellerich M, Meiser B, van Gelder T: Current issues in therapeutic drug monitoring of mycophenolic acid: Report of a roundtable discussion. Ther Drug Monit 23: 305-315, 2001
21. van Besouw NM, van der Mast BJ, Smak Gregoor PJ, Hesse CJ, Ijzermans JN, van Gelder T, Weimar W: Effect of mycophenolate mofetil on erythropoiesis in stable renal transplant patients is correlated with mycophenolic acid trough levels. Nephrol Dial Transplant 14: 2710-2713, 1999
22. Hesselink DA, van Hest RM, Mathot RA, Bonthuis F, Weimar W, de Bruin RW, van Gelder T: Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am J Transplant 5: 87-94, 2005
23. Le Meur Y, Buchler M, Lavaud S, Etienne I, Westeel PF, Thierry A: Therapeutic drug monitoring of MMF: A randomized multicenter study comparing concentration controlled versus fixed dose in kidney transplant recipients. Transplantation 82: 343-345, 2006